Thammasat university hospital
Pathum Thani, Changwat Pathum Thani, 12120, Thailand
Location status: Recruiting
NCT Number: NCT06367855
Researchers are considering Dexamethasone as preemptive medication before minimally invasive spine fusion surgery to minimize postoperative back pain with minimal side effects, aiming to enhance the effectiveness of surgery and improve patient outcomes.
Interested in participating?
Request Info50 year–80 year
All sexes
Interventional
Phase 4
Pathum Thani, Changwat Pathum Thani, 12120, Thailand
Location status: Recruiting
Surgery for spine fusion through a minimally invasive technique called MIS-TLIF has become increasingly popular nowadays due to various reasons such as lower blood loss and reduced need for blood transfusions, less postoperative back pain, and shorter surgical duration compared to the traditional technique known as TLIF. However, even after MIS TLIF, patients still experience issues such as wound or back pain, which can affect their physical activity and increase the risk of infection. Prolonged hospital stays lead to resource wastage.
In the Enhanced Recovery After Surgery (ERAS) program for spine surgery, preoperative medication, including Acetaminophen, NSAIDs, and Gabapentinoids, is recommended to alleviate postoperative back pain. However, even after implementing ERAS, patients undergoing MIS TLIF still experience pain, suggesting that further pain reduction strategies are needed. The use of Dexamethasone as preemptive medication has shown promising results in various surgeries, with minimal side effects and a manageable cost. Dexamethasone, administered via injection, has a longer duration of action compared to other steroids, making it suitable for preemptive use.
The main objective is to study the effectiveness of using Dexamethasone via intravenous injection before minimally invasive spine fusion surgery, known as MIS-TLIF, in reducing postoperative back pain.
The secondary objectives are to compare the rate of morphine usage for pain management after surgery between two groups.
To compare the side effects and adverse reactions of the medication, such as nausea and vomiting, surgical site infection rates, and blood sugar levels post-surgery.
To compare the fusion rates of the spinal bones. To compare the length of hospital stays after surgery.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
long-acting corticosteroid IV route
normal saline
Time frame: 24 hours, 2 weeks, 6 weeks, 12 weeks post operative period
postoperative VAS score at rest and motion for back pain
Time frame: 24 hours post operative period
rate of morphine usage for pain management
Time frame: 24 hours, 2 weeks, 6 weeks, 12 weeks post operative period
To compare the side effects and adverse reactions of the medication, such as nausea and vomiting, surgical site infection rates, and blood sugar levels post-surgery
Time frame: 6months
To compare the fusion rates of the spinal bones
Time frame: 1 year
To compare the length of hospital stays after surgery.
Contact information is provided by the study sponsor or research team.
Potsawat Surabotsopon
Other
Acronym: MIS-TLIF
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03884283
Bone Diseases, Degenerative Disc Disease
Long Beach, California, United States
View Trial DetailsNCT03321357
Bone Diseases, Degenerative Disc Disease
Naarden, Netherlands
View Trial DetailsNCT06935201
Behavior, Motor Activity
Stockholm, Sweden
View Trial DetailsNCT07045714
Bone Diseases, Musculoskeletal Diseases
San Pedro Garza García, Nuevo León, Mexico
View Trial Details